As of Sep 02
| +0.99 / +3.23%|
The 34 analysts offering 12-month price forecasts for AstraZeneca have a median target of 36.06, with a high estimate of 49.96 and a low estimate of 28.35. The median estimate represents a +13.83% increase from the last price of 31.68.
The current consensus among 35 polled investment analysts is to Hold stock in AstraZeneca. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.